<code id='382E641802'></code><style id='382E641802'></style>
    • <acronym id='382E641802'></acronym>
      <center id='382E641802'><center id='382E641802'><tfoot id='382E641802'></tfoot></center><abbr id='382E641802'><dir id='382E641802'><tfoot id='382E641802'></tfoot><noframes id='382E641802'>

    • <optgroup id='382E641802'><strike id='382E641802'><sup id='382E641802'></sup></strike><code id='382E641802'></code></optgroup>
        1. <b id='382E641802'><label id='382E641802'><select id='382E641802'><dt id='382E641802'><span id='382E641802'></span></dt></select></label></b><u id='382E641802'></u>
          <i id='382E641802'><strike id='382E641802'><tt id='382E641802'><pre id='382E641802'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:knowledge    - browse:29

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge